False000158475100015847512024-08-222024-08-22

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 23, 2024 (August 22, 2024)

 

 

Talis Biomedical Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40047

46-3122255

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1375 West Fulton Market

Suite 700

 

Chicago, Illinois

 

60607

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 433-3000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TLIS

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 19, 2024, Talis Biomedical Corporation (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) the Company’s quarterly report on Form 10-Q and disclosed that the Company had suspended all research and development activities as of June 30, 2024, anticipated commencing a voluntary petition under Chapter 11 of the United States Code and expected that the Company would be delisted from the Nasdaq Stock Market.

 

On August 22, 2024, the Company received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based upon Nasdaq’s review of the Company and pursuant to Nasdaq Listing Rule 5101 (the “Listing Rule”), Nasdaq believes that the Company is a “public shell,” and that the continued listing of its common stock is no longer warranted. Nasdaq’s notice also provided that, unless the Company timely appeals Nasdaq’s determination, it would be subject to delisting.

 

While the Company does not believe that it currently meets the definition of a shell company as defined in Rule 12b-2 of the Exchange Act, given the suspension of all of its research and development activities as of June 30, 2024, it does not intend to petition Nasdaq for a hearing to appeal Nasdaq’s determination. Accordingly, trading of the Company’s common stock will be suspended at the opening of business on September 3, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company’s common stock from listing and registration on the Nasdaq Stock Market.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

Exhibit Number

Description

104

Cover Page Interactive Data File (Embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Talis Biomedical Corporation

 

 

 

 

Date:

August 23, 2024

By:

/s/ Robert J. Kelley

 

 

 

Robert J. Kelley
Chief Executive Officer

 

 

v3.24.2.u1
Document And Entity Information
Aug. 22, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 22, 2024
Entity Registrant Name Talis Biomedical Corporation
Entity Central Index Key 0001584751
Entity Emerging Growth Company true
Securities Act File Number 001-40047
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-3122255
Entity Address, Address Line One 1375 West Fulton Market
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Chicago
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60607
City Area Code 650
Local Phone Number 433-3000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TLIS
Security Exchange Name NASDAQ
Talis Biomedical (NASDAQ:TLIS)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Talis Biomedical.
Talis Biomedical (NASDAQ:TLIS)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Talis Biomedical.